Publicaciones en las que colabora con Eduardo Núñez (9)

2023

  1. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  2. Peritoneal and Urinary Sodium Removal in Refractory Congestive Heart Failure Patients Included in an Ambulatory Peritoneal Dialysis Program: Valuable for Monitoring the Course of the Disease

    CardioRenal Medicine, Vol. 13, Núm. 1, pp. 211-220

  3. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  4. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

2021

  1. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 5, pp. 475-483

  2. Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 616-623

2020

  1. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 3792-3800

2018

  1. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

    Clinical Cardiology, Vol. 41, Núm. 4, pp. 476-480

  2. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

    Circulation, Vol. 137, Núm. 13, pp. 1320-1330